PMA device
Onclarity HPV Assay
Becton, Dickinson and Company · Kit, Dna Detection, Human Papillomavirus (MAQ, Class III) · First FDA decision Mar 12, 2025, newest Mar 12, 2025Cervical cancer and HPV
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
2
Naming "Onclarity HPV"
MAUDE reports
145
Brand "Onclarity HPV", since 2015
PubMed studies
54
Mentioning "Onclarity HPV"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Onclarity HPV Assay
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Onclarity HPV AssayPMA supplement
P160037-S021 · Decided Mar 12, 2025 · 29 days after receipt · Normal 180 Day Track No User Fee
Device type: KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS (MAQ) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Screening for Cervical Cancer with Human Papillomavirus (HPV) TestingNational analysisReview closedCAG-00442NUpdated Sep 22, 2026
- Screening for Cervical Cancer with Human Papillomavirus (HPV)National determinationOn the books210.2.1Updated Jun 17, 2020
Clinical trials
Device studies on ClinicalTrials.gov that name "Onclarity HPV", any status and sponsor, newest update first.
- BD Onclarity HPV Assay on the BD COR Instrument: Self-collected Vaginal Swabs ValidationNot yet recruiting
Indiana UniversityAcademic, hospital or other
NCT07909499 · 40 participants (planned) · Start Nov 15, 2026 · Primary completion Dec 15, 2026
Device: BD Cor OnClarity Self-Collection · For: Healthy Subjects; HPV
Sites: Indianapolis, Indiana
1 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Onclarity HPV", and for the whole product code for context.
This brand
145 reports: 145 malfunction, 0 injury, 0 death
Whole product code MAQ
310 reports: 306 malfunction, 3 injury, 0 death
Newest reports for this brand
BECTON, DICKINSON & CO. (Sparks)
1119779-2026-01900 · Received Sep 16, 2026 · Event dated Jun 24, 2026
Device type: Kit, Dna Detection, Human Papillomavirus (MAQ)
Device problem as coded: Incorrect, Inadequate or Imprecise Result or Readings
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- BD COR System Software. Model Number: 444829.Open, Classified
Z-2162-2025 · Started Jun 23, 2025 · Posted by FDA Jul 23, 2025
Reason given: Potential for functionality issue that supports the Over labeling feature and could lead to possible false negative results.
Cause as FDA categorized it: Under Investigation by firm · Device type: Kit, Dna Detection, Human Papillomavirus (MAQ)
Published research
The most relevant PubMed records for "Onclarity HPV"[tiab]. The summary above synthesizes these.
- Performance of BD Onclarity HPV assay on FLOQSwabs vaginal self-samples.
Martinelli M, Latsuzbaia A, Bonde J, et al. · Microbiol Spectr · 2024Research Support, Non-U.S. Gov't
- Clinical performance of Onclarity HPV assay and Cobas HPV test in detection of cervical precancer and cancer in Chinese women.
Li T, Wu Z, Jiang M, et al. · Gynecol Oncol · 2020Research Support, Non-U.S. Gov't
- Validation of BD Onclarity HPV Assay on Vaginal Self-Samples versus Cervical Samples Using the VALHUDES Protocol.
Latsuzbaia A, Vanden Broeck D, Van Keer S, et al. · Cancer Epidemiol Biomarkers Prev · 2022Research Support, Non-U.S. Gov't
- 2020 list of human papillomavirus assays suitable for primary cervical cancer screening.
Arbyn M, Simon M, Peeters E, et al. · Clin Microbiol Infect · 2021Meta-Analysis, Systematic Review
- Evaluation of BD Onclarityࡊ HPV Assay on Self-Collected Vaginal and First-Void Urine Samples as Compared to Clinician-Collected Cervical Samples: A Pilot Study.
Martinelli M, Giubbi C, Sechi I, et al. · Diagnostics (Basel) · 2022
- Evaluation of the Onclarity HPV assay on the high-throughput COR system.
Taylor SN, Eckert K, Rucki AA, et al. · Expert Rev Mol Diagn · 2021
- Onclarity Performance in Human Papillomavirus DNA Detection in Formalin-Fixed Paraffin-Embedded Cervical Samples.
Bottari F, Passerini R, Renne G, et al. · J Low Genit Tract Dis · 2021
- Applying Results of Extended Genotyping to Management of Positive Cervicovaginal Human Papillomavirus Test Results: Enduring Guidelines.
Massad LS, Clarke MA, Perkins RB, et al. · J Low Genit Tract Dis · 2025Practice Guideline
- Comparison Study of BD Onclarity HPV With digene HC2 High-Risk HPV DNA Test and Roche Cobas 4800 HPV for Detecting High-Risk Human Papillomavirus in Japan.
Nakamura M, Nakade K, Orisaka S, et al. · Am J Clin Pathol · 2019Comparative Study, Evaluation Study
- Profile of the BD HPV OnclarityTM assay.
Bottari F, Iacobone AD · Expert Rev Mol Diagn · 2019Review
- The BD Onclarity HPV Assay on Samples Collected in SurePath Medium Meets the International Guidelines for Human Papillomavirus Test Requirements for Cervical Screening.
Ejegod D, Bottari F, Pedersen H, et al. · J Clin Microbiol · 2016Validation Study
- Onclarity Human Papillomavirus Extended Genotyping in the Management of Cervical Intraepithelial Neoplasia 2+ Lesions.
Bottari F, Iacobone AD, Boveri S, et al. · J Low Genit Tract Dis · 2019Evaluation Study
Other devices of this type
Also filed under product code MAQ.
- cobas HPVRoche Molecular Systems, Inc. · PMA 2026
- BD Onclarity HPV Assay Reagent Pack (SKU 444075) and BD COR HPV Extraction Trough (SKU 444074)Becton, Dickinson and Company · PMA 2026
- Digene Hybrid Capture 2 (HC2) Hpv Dna TestsQiagen Gaithersburg, Inc. · PMA 2015
- Alinity m HR HPVAbbott Molecular, Inc. · PMA 2026
- Cervista Hpv Hr and Genfind KitHologic, Inc. · PMA 2014
- Cervista Hpv 16/18Hologic, Inc. · PMA 2014
- Digene HC2 High Risk Hpv Dna Test and Digene HC2 Hpv Dna TestQiagen Gaithersburg, Inc. · PMA 2014
- Digene Hybrid CAPTURE2Qiagen Gaithersburg, Inc. · PMA 2009
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.